Loading market dashboard
Spectral AI, Inc.
MDAIHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration (“FDA”).
DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView® System. With this classification, Spectral AI is authorized to commence commercial distribution activities in the United States.
Spectral AI NASDAQ: MDAI said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter research and development revenue tied to the completion of work under a federal contract.
Spectral AI, Inc. (MDAI) Q1 2026 Earnings Call Transcript
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA
DALLAS, April 30, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received the “Small Business Innovator Award” at the inaugural Texas Innovation Conference, held on April 22-23, 2026 at the campus of Texas Christian University. The conference highlighted organizations and thought leaders that are turning research into real-world results, bringing together a select group of high-impact innovators, including startups, researchers, and ecosystem leaders.
DALLAS, April 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 12, 2026 after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results.
DALLAS, April 22, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today shared a recap from the 2026 Annual Meeting of the American Burn Association, held April 14-17, 2026 in Orlando, Florida.
DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its 2026 Annual Meeting of Stockholders (“Annual Meeting”) will take place at 9:30 a.m. Central Daylight Time on Friday, May 29, 2026.
DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its participation in the upcoming Annual Meeting of the American Burn Association, being held April 14-17, 2026 in Orlando, Florida. The Company's DeepView® System will be on display at Booth 601.
DALLAS, April 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of David McGuire as the Company's Chief Financial Officer, effective May 4, 2026.
Spectral AI (NASDAQ: MDAI - Get Free Report) and ADM Tronics Unlimited (OTCMKTS:ADMT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Analyst Ratings This is a breakdown
Spectral AI (NASDAQ: MDAI) executives said fiscal 2025 marked a "pivotal year" as the company advanced its DeepView burn diagnostic system toward potential FDA clearance and strengthened its funding profile, highlighted by a new award under its longstanding BARDA partnership. DeepView FDA path and clinical data Chief Executive Officer Vincent Capone said the company's June 2025
Spectral AI (NASDAQ: MDAI - Get Free Report) is expected to announce its Q4 2025 results after the market closes on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $2.9230 million for the quarter. Investors may visit the the company's upcoming Q4 2025 earning results page for
Spectral AI, Inc. (MDAI) Q4 2025 Earnings Call Transcript
Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million Cash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (“AI”) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2025”) and full year (“FY 2025”) ended December 31, 2025 and provided an update on its ongoing activities related to the commercialization of its proprietary, AI-driven DeepView® System for burn indication. “2025 was a pivotal year for Spectral AI, highlighted by the submission of our De Novo 510(k) application to the U.S. Food and Drug Administration (“FDA”) of our DeepView System for burn indication,” said Vincent Capone, Chief Executive Officer of Spectral AI.
Here's what investors need to know.
DALLAS, March 18, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received $31.7 million in funding from the Biomedical Advanced Research and Development Authority (“BARDA”) to accelerate and support additional feature aspects for the Company's DeepView® System, its AI-driven burn wound imaging technology. As part of the ongoing partnership, Spectral AI has committed to provide an additional $9.7 million to the total overall development costs associated with these feature advancements.
DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 on Tuesday, March 24, 2026 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.
